,9 A retrospective review of 1203 patients with pulmonary adenocarcinoma reported that the percentage of tumours tested for EGFR mutation was 54%, ALK mutation 51%, ROS1 mutation 43%, BRAF mutation 29%, RET mutation 17%, MET exon 14 skipping 15% and Erb-B2 receptor tyrosine kinase 2 (ERBB2) mutation 11%.10 Here, ERBB2 is linked to neoplasm.